Evidence map›Paper›PMID 34242573›Full record

ArticleCancer cell2021

Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.

Elizabeth A Griffiths, Brahm H Segal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. COVID-19 Vaccines, Effectiveness, and Immune Responses.International journal of molecular sciences · 2022
    Review
  14. Article
  15. COVID-19 Impact on Chronic Myeloid Leukemia Patients.Journal of personalized medicine · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Elizabeth A GriffithsLeukemia Division, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Electronic address: Elizabeth.Griffiths@RoswellPark.org.
Brahm H SegalDepartment of Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Electronic address: Brahm.Segal@RoswellPark.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several studies in this issue of Cancer Cell add to our knowledge of the heterogeneity of immune responses to vaccination among patients with cancer and identify important areas for future research.

Indexed as

ImmunityCOVID-19COVID-19 VaccinesHumansNeoplasmsPublic Health SurveillanceSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID34242573
PMCPMC8253695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.